What constitutes optimal neurohumoral antagonism in chronic heart failure? - Wikidata - awgldk - TriplyDB

What constitutes optimal neurohumoral antagonism in chronic heart failure?

What constitutes optimal neurohumoral antagonism in chronic heart failure?

http://www.wikidata.org/entity/Q47814853

about

What constitutes optimal neurohumoral antagonism in chronic heart failure?

http://www.wikidata.org/entity/Q47814853

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

What constitutes optimal neurohumoral antagonism in chronic heart failure?

@en

What constitutes optimal neurohumoral antagonism in chronic heart failure?

@nl

type

label

What constitutes optimal neurohumoral antagonism in chronic heart failure?

@en

What constitutes optimal neurohumoral antagonism in chronic heart failure?

@nl

prefLabel

What constitutes optimal neurohumoral antagonism in chronic heart failure?

@en

What constitutes optimal neurohumoral antagonism in chronic heart failure?

@nl

P1433

Q47814853-096F623C-4D19-4819-800F-790D4E89E00F

P1476

Q47814853-63081A95-2EF3-4AE4-AE1A-5730D99B043E

P2093

Q47814853-32EE7371-044E-459D-96D5-F0654D722216

P2860

Q47814853-0097E4B0-0785-4857-ACCF-34EDEA9654CF

Q47814853-05740BA4-A098-4CCD-8D17-A450461ECFB4

Q47814853-094AF2BF-7A11-49B6-81B2-5E7C7A0CC0D3

Q47814853-131110B6-7CB0-4491-9872-8087C30006AB

Q47814853-1517268C-7B8C-4A87-A901-AF6A7DDD32A2

Q47814853-1B98F2A1-8615-49B0-B04D-65F6B8196B6B

Q47814853-1DD62109-301F-47F3-BB63-528B5C6B40B9

Q47814853-2318936E-1AFB-4FEF-9C93-03027EA1B9D7

Q47814853-28D32B49-F4F2-4F3A-A808-17B77430AED4

Q47814853-2E20A448-CEED-4C30-AA57-7DC37E7FC650

P304

Q47814853-70BA62FD-A902-45B5-B590-E865A020C626

P31

Q47814853-090E5DB9-DE33-4F24-94D3-9D973F9B81DE

P356

Q47814853-C6746DDD-7177-4C44-A6E2-DE8CC4F5BA86

P407

Q47814853-D15D82CD-52E8-4301-BD14-94583885A2C0

P433

Q47814853-82A2B323-8D04-4453-A8BD-0C1FCF06ADD1

P478

Q47814853-5B5A5C1E-7022-41C9-93E6-2593C0119856

P50

Q47814853-353BA63B-0102-4DB3-AB64-476D9EBD63CF

P577

Q47814853-FE8A84D1-C586-4A1A-BDA5-F9B30EE1FB59

P698

Q47814853-82A0EA02-EEAE-4B09-9338-5B9601B3CA2A

P356

HEARTJNL-2015-308039

P1433

P1476

What constitutes optimal neurohumoral antagonism in chronic heart failure?

@en

P2093

Athar Ali Tajik

http://www.w3.org/2001/XMLSchema#string

P2860

2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Epidemiology and risk profile of heart failure

ELITE II and Val-HeFT are different trials: together what do they tell us?

Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances

Effect of nesiritide in patients with acute decompensated heart failure

Angiotensin-neprilysin inhibition versus enalapril in heart failure

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

P304

1922-1932

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/HEARTJNL-2015-308039

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth Dickstein

P577

2016-10-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27742799

http://www.w3.org/2001/XMLSchema#string